Phase 4
Completed N=120
A Study to Assess the Immunogenicity and Safety of CSL's 2012/2013 Formulation of Enzira® Vaccine in Healthy Volunteers
Influenza, Human
Source: ClinicalTrials.gov NCT01591837 ↗
Enrolled (actual)
120
Serious AEs
0.0%
Results posted
Nov 2013
Primary outcomePrimary: The Percentage of Evaluable Participants Achieving Seroconversion or Significant Increase in Antibody Titre. — 79.7; 55.9; 86.4; 64.4 percentage of participants
Summary
This is a study to assess the immune (antibody) response and safety of the 2012/2013 formulation of Enzira® (CSL Influenza vaccine) in healthy adult volunteers aged 18 years or older.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY The Percentage of Evaluable Participants Achieving Seroconversion or Significant Increase in Antibody Titre. |
79.7; 55.9; 86.4; 64.4; 59.3; 18.6 | — |
| PRIMARY The Geometric Mean Fold Increase (GMFI) in Antibody Titre After Vaccination. |
17.51; 7.78; 21.80; 9.88; 7.34; 2.44 | — |
| PRIMARY The Percentage of Evaluable Participants Achieving a HI Titre ≥ 40 or Single Radial Haemolysis (SRH) Area ≥ 25 mm2. |
94.9; 84.7; 100.0; 100.0; 66.1; 18.6 | — |
| SECONDARY Frequency and Intensity of Any Solicited Adverse Events (AEs). |
46.7; 18.3; 0.0; 3.3; 15.0; 6.7 | — |
| SECONDARY Frequency of Any Unsolicited AEs. |
53.3; 36.7 | — |
Eligibility Criteria
Inclusion Criteria
- Males or females aged 18 years or older at the time of vaccination.
- Females of child-bearing potential (i.e., ovulating, pre-menopausal, not surgically sterile) must be abstinent or be willing to use a medically accepted contraceptive regimen for the duration of the study. Females of child-bearing potential must return a negative urine pregnancy test result prior to vaccination with the vaccine.
Exclusion Criteria
- Known hypersensitivity to a previous vaccination with influenza vaccine or allergy to eggs, ovalbumin, chicken protein, neomycin, polymyxin, or any components of the vaccine.
- Clinical signs of an active infection.
- A clinically significant medical condition.
- Vaccination with a seasonal or experimental influenza virus vaccine in the 6 months preceding study entry.
- Females who are pregnant or lactating.
Data sourced from ClinicalTrials.gov (NCT01591837). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.